28 May 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Notice of FY21 Trading Update
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces that it will issue a trading update for the year ended 31 May 2021 on 8 June 2021.
Analyst and investor presentations
Dr Adam M Hill, Chief Executive Officer and Matthew Hall, Chief Financial Officer will host an online presentation for analysts at 11:30am BST on 8 June 2021. For registration details please contact Alexander Davis of FTI Consulting at Alexander.Davis@fticonsulting.com or 020 3727 1000.
Dr Adam M Hill and Matthew Hall will also host a live presentation on Investor Meet Company at 4:30pm BST on 8 June 2021 which will be open to all existing Oncimmune shareholders and potential new investors. Access to Investor Meet Company is free and interested parties are invited to register their attendance on the following link: https://www.investormeetcompany.com/oncimmune-holdings-plc/register-investor
Investors who already follow Oncimmune Holdings plc on the Investor Meet Company platform will automatically be invited. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9:00am BST the day before the meeting or at any time during the live presentation.
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
Zeus Capital Limited (Nominated Adviser)
Andrew Jones, Daniel Harris, James Hornigold
+44 (0)20 3829 5000
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Claes Spång
+44 (0)20 3705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.
Our understanding of the immune system enables us to harness its sophisticated response to disease to detect cancer earlier and to support the development of better therapies. The key to improving cancer survival is early detection and better selection for therapy. As a company, we are driven by our passion to improve cancer survival and to give people extra time.
Oncimmune's ImmunoINSIGHTS platform enables life science organisations to optimise drug development and delivery, leading to more effective targeted as well as safer treatments for patients. Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.
Oncimmune, headquartered at its laboratory facility in Nottingham, UK, and has a discovery research centre in Dortmund, Germany.
For more information, visit www.oncimmune.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
